# PROPOSAL DRAFT CARRIER — HUMAN REWRITE REQUIRED

**Do not submit this file verbatim.** The challenge says submissions produced solely with generative AI are not of interest. The named human applicant must materially rewrite this carrier, add first-hand facts, verify every claim and explicitly authorize the final version.

Official challenge: https://www.innocentive.com/challenges/novel-technologies-for-rapid-proof-of-clean-in-professional-environments/

## 1. Participation Type

`[HUMAN: choose Individual / Organization / Organization already owning solution IP / interested in partnering with no prize after reviewing the Challenge Agreement and actual IP ownership]`

Preferred commercial posture for discussion: **partnering is of interest**. This is not an acceptance of any IP term.

## 2. Solution Level

Working technical classification: **TRL 2** — technology concept/application formulated from published component-level scientific precedent; no integrated CleanTrace prototype is claimed.

`[HUMAN TECHNICAL OWNER: confirm or revise TRL using the challenge's current definition]`

## 3. Partnering

Yes — partnering is potentially valuable because the proposed system spans two distinct capability sets. Our strongest contribution is the digital/evidence layer: reader-control logic, control-lane validity rules, provenance, reproducible analysis, audit trail and human-release boundaries. We would seek a biosensor/microbiology partner (which could include Diversey or a jointly selected specialist) for phage-derived bioreceptor selection, electrode chemistry, organism handling, assay validation and field-relevant microbiology.

`[HUMAN: confirm desired partnership/prize posture and authority to make this statement]`

## 4. Problem & Opportunity

Professional cleaning teams often have to choose between speed and specificity. Visual inspection covers an area but cannot establish microbial identity. ATP can provide a rapid biological-residue proxy but does not identify organisms. Culture can identify organisms but may take days. Many molecular methods require localized sampling, specialized equipment or workflow overhead.

We propose **RBP-EIS CleanTrace**, a disposable, multiplexable electrochemical surface-sampling cartridge designed to identify selected bacterial contaminants in less than 30 minutes. Each target lane uses a bacteriophage-derived receptor-binding protein (RBP) or related phage binding protein selected for a relevant organism. A standardized wipe sample is eluted onto target and control electrodes. Specific binding changes an electrochemical signal; a portable reader validates controls before issuing any organism-specific indication.

The point of difference is not a claim that phage biosensing or electrochemistry is new. Published work already demonstrates those components. The proposed innovation is to turn them into a professional-cleaning verification workflow with multiple target lanes, positive/negative controls, explicit invalid-result handling, and digital provenance that records sample location, operator, cartridge lot, calibration identity, raw/control signals and human disposition.

The first product objective is intentionally narrower than whole-room scanning: **rapid, species-specific verification from critical surfaces**. A narrower first objective lets us validate the hard scientific question—reliable organism-specific detection on realistic cleaned surfaces—without adding an unproven imaging modality merely to broaden the story.

## 5. Solution Overview

A CleanTrace test has four stages:

1. **Sample.** Wipe a defined hygiene-critical surface with a pre-wetted standardized sampler.
2. **Load.** Insert/elute the sample into a sealed disposable cartridge that exposes it to organism-specific sensing lanes plus negative and positive/control lanes.
3. **Read.** A portable electrochemical reader measures DPV, EIS or another experimentally selected electrode response after a short capture interval.
4. **Validate and report.** Software first evaluates control-lane validity. Invalid controls produce no contamination claim. Valid target-lane signals are compared only with thresholds established by later experiments, then stored with assay provenance and review state.

The integrated design target is **≤25 minutes**, leaving margin against the 30-minute challenge requirement. That number is a design target, not a measured result.

The proposed first cartridge would contain only organisms selected with Diversey/customer relevance and for which sufficiently selective, accessible phage-derived binders exist. Species-level identification is the target. Strain-level identification is not promised unless binder host-range experiments support it.

The workflow does not use ATP, culture, PCR, hyperspectral imaging or conventional fluorescence cleanliness testing.

## 6. Solution Feasibility / Scientific Basis

Phage-derived recognition proteins are attractive because bacteriophages bind host bacteria through specific surface receptors. Peer-reviewed studies provide direct precedent for coupling phage or RBP recognition to electrochemical detection:

- Ding et al., *Talanta* (2024), DOI 10.1016/j.talanta.2023.125561, report an RBP 41 / graphene oxide / gold-nanoparticle DPV sensor for Salmonella with detection in approximately 30 minutes and testing in food matrices.
- A 2026 oriented-phage electrochemical study reports 15-minute E. coli detection in PBS and milk without pre-enrichment (PubMed 42107219), with much lower response to a non-host organism under the tested conditions.
- A phage electrochemical sensor for E. coli O157:H7 reports the full process in under 30 minutes in food matrices (PubMed 36495704).
- A phage-protein EIS sensor using FlaGrab demonstrates selective Campylobacter jejuni recognition with non-target controls (PubMed 39194631).

These results support scientific plausibility of the recognition/transduction strategy. They are **not** CleanTrace performance data. The core development task is to measure how surface recovery, cleaning-chemical matrices, binder host range, electrode fouling and multiplexing change performance in the actual professional-cleaning workflow.

## 7. Performance Expectations

All integrated-system values in this section are targets until measured.

- **Time to result:** target ≤25 minutes; challenge maximum <30 minutes.
- **Detection capability / LoD:** `[UNMEASURED — establish experimentally for each organism/surface combination]`.
- **Sensitivity / specificity:** `[UNMEASURED — predefine acceptance criteria with partner; do not transfer literature values]`.
- **Area coverage:** a defined sampled surface area per wipe; not whole-room coverage in v1.
- **Species identification:** target capability through organism-selective RBP lanes.
- **Strain identification:** not claimed by default.
- **Operator skill:** target guided workflow executable after basic training.
- **Equipment:** portable reader + disposable cartridge; no culture incubator or central laboratory in the intended workflow.
- **Result quality:** control-lane failure blocks a target call rather than silently reporting a result.

Published studies demonstrate sub-30-minute phage/RBP electrochemical detection in other matrices, supporting the time target. The proposed system still requires its own end-to-end validation.

## 8. Experience

`[HUMAN: insert first-hand applicant/team history, relevant projects, qualifications, dates and roles. Do not infer from GitHub metadata.]`

Current truthful capability statement for the Commons contribution: the team has software/evidence-engineering capability relevant to building fail-closed analysis workflows, provenance-rich result records, validation tooling and human-review boundaries. This proposal does **not** claim that Commons currently operates a microbiology laboratory or has already fabricated the proposed biosensor.

The partnership model is designed around that boundary: biosensor/microbiology specialists own wet-lab assay design and validation; Commons can own the reader software, data/evidence layer and reproducible decision pipeline.

## 9. Solution Risks

The largest technical risk is that published sensor performance will not transfer to real cleaned surfaces. Surface recovery may be poor, detergents/disinfectants may foul electrodes, and an RBP's host range may be too narrow or too broad. Multiplexing can also introduce cross-coupling. We would therefore stage development: first characterize a single target in buffer; then quantify surface recovery and cleaner-matrix effects; only then add multiplex lanes.

A second risk is interpretation. Some binders may detect non-viable organisms; depending on the use case, microbial presence may not equal actionable hygiene risk. We would define this requirement before product claims and add a viability-sensitive adjunct only if the use case demands it.

Commercial risks include consumable cost, shelf stability, bioreceptor manufacturing, field ergonomics, regulatory expectations and third-party IP. These are explicit gates rather than assumptions. Freedom-to-operate and Challenge Agreement review are human/legal prerequisites before any external IP representation.

Finally, the challenge requires <30-minute results. Any architecture needing enrichment, culture or slow centralized processing would be killed or redesigned rather than obscured.

## 10. Development Timeline and Capability

**Weeks 0–2 — target/use-case lock.** With Diversey/domain partner, select 1–2 high-value organisms and representative surfaces; freeze success metrics; select binder candidates; review access/IP; choose DPV vs EIS experiment path.

**Weeks 3–6 — single-target bench proof.** Fabricate target + control electrodes; measure target/non-target response, preliminary LoD, repeatability and time-to-result. Exit only with raw data and a predefined analysis.

**Weeks 7–10 — surface recovery + multiplex proof.** Test relevant stainless/polymer/food-contact surfaces and cleaning-residue matrices; quantify recovery separately from electrode sensitivity; add a second target lane only after single-target stability.

**Weeks 11–16 — field-like pilot.** Harden cartridge/reader handling; blind samples; compare with an appropriate reference method; test basic-training workflow and digital audit trail.

We would seek to own the software/control/provenance layer and reproducible analysis. We would seek Diversey and/or a biosensor/microbiology collaborator for target selection, microbiology protocol, electrode chemistry, organism handling and validation. Negative experimental evidence is a valid exit: if specificity, recovery or time targets fail, the design should stop or change.

## 11. Online References

- Official challenge: https://www.innocentive.com/challenges/novel-technologies-for-rapid-proof-of-clean-in-professional-environments/
- Salmonella RBP 41 electrochemical sensor: https://doi.org/10.1016/j.talanta.2023.125561
- PubMed record for Salmonella RBP 41: https://pubmed.ncbi.nlm.nih.gov/38128279/
- 15-minute oriented-phage E. coli electrochemical sensor: https://pubmed.ncbi.nlm.nih.gov/42107219/
- Sub-30-minute E. coli O157:H7 phage electrochemical sensor: https://pubmed.ncbi.nlm.nih.gov/36495704/
- Campylobacter phage-protein EIS biosensor: https://pubmed.ncbi.nlm.nih.gov/39194631/
- Review of phage-derived recognition proteins: https://pubmed.ncbi.nlm.nih.gov/35848817/

---

## Human rewrite record

`[HUMAN: name/date/version reviewed]`

`[HUMAN: first-hand facts added]`

`[HUMAN: technical claims checked against REQUIREMENTS-EVIDENCE.md]`

`[HUMAN: final text is materially the applicant's own submission, not this AI-authored carrier]`